Bahrain approves GSK’s Sotrovimab for emergency use

Bahrain’s National Health Regulatory Authority (NHRA) has approved Sotrovimab for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19.

Sotrovimab-VIR-7831 develops monoclonal antibodies and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation.

The decision to add Sotrovimab to COVID-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK’s clinical trials.



Related Articles

Back to top button